nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluphenazine—ABCB1—Methylprednisolone—ankylosing spondylitis	0.121	0.214	CbGbCtD
Fluphenazine—CYP2E1—Dexamethasone—ankylosing spondylitis	0.0903	0.16	CbGbCtD
Fluphenazine—ABCB1—Betamethasone—ankylosing spondylitis	0.0785	0.139	CbGbCtD
Fluphenazine—ABCB1—Prednisolone—ankylosing spondylitis	0.0775	0.137	CbGbCtD
Fluphenazine—ABCB1—Prednisone—ankylosing spondylitis	0.0732	0.129	CbGbCtD
Fluphenazine—Psychotic behaviour—Methylprednisolone—ankylosing spondylitis	0.0482	0.164	CcSEcCtD
Fluphenazine—ABCB1—Dexamethasone—ankylosing spondylitis	0.0457	0.0808	CbGbCtD
Fluphenazine—CYP2D6—Dexamethasone—ankylosing spondylitis	0.043	0.0761	CbGbCtD
Fluphenazine—ABCB1—Methotrexate—ankylosing spondylitis	0.0367	0.0649	CbGbCtD
Fluphenazine—Pigmentation skin—Prednisone—ankylosing spondylitis	0.0126	0.0429	CcSEcCtD
Fluphenazine—Hypotensive—Dexamethasone—ankylosing spondylitis	0.00724	0.0247	CcSEcCtD
Fluphenazine—Hypotensive—Betamethasone—ankylosing spondylitis	0.00724	0.0247	CcSEcCtD
Fluphenazine—Pigmentation disorder—Prednisone—ankylosing spondylitis	0.00689	0.0235	CcSEcCtD
Fluphenazine—Menstruation irregular—Prednisolone—ankylosing spondylitis	0.00571	0.0195	CcSEcCtD
Fluphenazine—Systemic lupus erythematosus—Triamcinolone—ankylosing spondylitis	0.00526	0.0179	CcSEcCtD
Fluphenazine—Menstruation irregular—Triamcinolone—ankylosing spondylitis	0.00526	0.0179	CcSEcCtD
Fluphenazine—Menstruation irregular—Methylprednisolone—ankylosing spondylitis	0.00524	0.0179	CcSEcCtD
Fluphenazine—Menstruation irregular—Dexamethasone—ankylosing spondylitis	0.00477	0.0163	CcSEcCtD
Fluphenazine—Menstruation irregular—Betamethasone—ankylosing spondylitis	0.00477	0.0163	CcSEcCtD
Fluphenazine—Dermatitis atopic—Prednisolone—ankylosing spondylitis	0.00427	0.0146	CcSEcCtD
Fluphenazine—Glaucoma—Prednisolone—ankylosing spondylitis	0.0042	0.0143	CcSEcCtD
Fluphenazine—Menstruation irregular—Prednisone—ankylosing spondylitis	0.00415	0.0142	CcSEcCtD
Fluphenazine—Dermatitis atopic—Triamcinolone—ankylosing spondylitis	0.00393	0.0134	CcSEcCtD
Fluphenazine—Glaucoma—Triamcinolone—ankylosing spondylitis	0.00386	0.0132	CcSEcCtD
Fluphenazine—Appetite absent—Methotrexate—ankylosing spondylitis	0.00386	0.0132	CcSEcCtD
Fluphenazine—Glaucoma—Methylprednisolone—ankylosing spondylitis	0.00386	0.0132	CcSEcCtD
Fluphenazine—Glaucoma—Betamethasone—ankylosing spondylitis	0.00351	0.012	CcSEcCtD
Fluphenazine—Glaucoma—Dexamethasone—ankylosing spondylitis	0.00351	0.012	CcSEcCtD
Fluphenazine—Dermatitis atopic—Prednisone—ankylosing spondylitis	0.00311	0.0106	CcSEcCtD
Fluphenazine—Leukocytosis—Methylprednisolone—ankylosing spondylitis	0.00309	0.0105	CcSEcCtD
Fluphenazine—Glaucoma—Prednisone—ankylosing spondylitis	0.00305	0.0104	CcSEcCtD
Fluphenazine—Leukocytosis—Dexamethasone—ankylosing spondylitis	0.00281	0.00958	CcSEcCtD
Fluphenazine—Leukocytosis—Betamethasone—ankylosing spondylitis	0.00281	0.00958	CcSEcCtD
Fluphenazine—Leukocytosis—Prednisone—ankylosing spondylitis	0.00245	0.00835	CcSEcCtD
Fluphenazine—Anaphylactoid reaction—Prednisolone—ankylosing spondylitis	0.00237	0.0081	CcSEcCtD
Fluphenazine—Cardiac arrest—Prednisolone—ankylosing spondylitis	0.00218	0.00745	CcSEcCtD
Fluphenazine—Anaphylactoid reaction—Triamcinolone—ankylosing spondylitis	0.00218	0.00745	CcSEcCtD
Fluphenazine—Anaphylactoid reaction—Methylprednisolone—ankylosing spondylitis	0.00218	0.00743	CcSEcCtD
Fluphenazine—Cardiac arrest—Triamcinolone—ankylosing spondylitis	0.00201	0.00685	CcSEcCtD
Fluphenazine—Cardiac arrest—Methylprednisolone—ankylosing spondylitis	0.002	0.00684	CcSEcCtD
Fluphenazine—Anaphylactoid reaction—Betamethasone—ankylosing spondylitis	0.00198	0.00676	CcSEcCtD
Fluphenazine—Anaphylactoid reaction—Dexamethasone—ankylosing spondylitis	0.00198	0.00676	CcSEcCtD
Fluphenazine—Lethargy—Dexamethasone—ankylosing spondylitis	0.00196	0.00667	CcSEcCtD
Fluphenazine—Lethargy—Betamethasone—ankylosing spondylitis	0.00196	0.00667	CcSEcCtD
Fluphenazine—Asthma—Triamcinolone—ankylosing spondylitis	0.00183	0.00623	CcSEcCtD
Fluphenazine—Cardiac arrest—Betamethasone—ankylosing spondylitis	0.00182	0.00622	CcSEcCtD
Fluphenazine—Cardiac arrest—Dexamethasone—ankylosing spondylitis	0.00182	0.00622	CcSEcCtD
Fluphenazine—Urine output increased—Methotrexate—ankylosing spondylitis	0.00174	0.00593	CcSEcCtD
Fluphenazine—Gynaecomastia—Methotrexate—ankylosing spondylitis	0.00172	0.00587	CcSEcCtD
Fluphenazine—Lethargy—Prednisone—ankylosing spondylitis	0.0017	0.00581	CcSEcCtD
Fluphenazine—Upper respiratory tract infection—Triamcinolone—ankylosing spondylitis	0.0017	0.00579	CcSEcCtD
Fluphenazine—Polyuria—Methotrexate—ankylosing spondylitis	0.00159	0.00542	CcSEcCtD
Fluphenazine—Photosensitivity—Methotrexate—ankylosing spondylitis	0.00159	0.00542	CcSEcCtD
Fluphenazine—Cardiac arrest—Prednisone—ankylosing spondylitis	0.00159	0.00541	CcSEcCtD
Fluphenazine—Renal failure acute—Methotrexate—ankylosing spondylitis	0.00151	0.00515	CcSEcCtD
Fluphenazine—CALM3—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00149	0.0105	CbGpPWpGaD
Fluphenazine—Dermatitis exfoliative—Methotrexate—ankylosing spondylitis	0.00148	0.00504	CcSEcCtD
Fluphenazine—Anaphylactoid reaction—Methotrexate—ankylosing spondylitis	0.00144	0.00492	CcSEcCtD
Fluphenazine—CALM1—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00144	0.0102	CbGpPWpGaD
Fluphenazine—CALM2—Antigen activates B Cell Receptor (BCR) leading to generation of second messengers—CD79A—ankylosing spondylitis	0.00144	0.0102	CbGpPWpGaD
Fluphenazine—CALM2—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00143	0.0101	CbGpPWpGaD
Fluphenazine—CALM1—Endochondral Ossification—RUNX3—ankylosing spondylitis	0.00143	0.0101	CbGpPWpGaD
Fluphenazine—Lethargy—Methotrexate—ankylosing spondylitis	0.00142	0.00486	CcSEcCtD
Fluphenazine—Erythema—Prednisolone—ankylosing spondylitis	0.00138	0.00472	CcSEcCtD
Fluphenazine—CALM3—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00138	0.00975	CbGpPWpGaD
Fluphenazine—CALM1—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00133	0.00943	CbGpPWpGaD
Fluphenazine—CALM2—Calcium signaling in the CD4+ TCR pathway—CD40LG—ankylosing spondylitis	0.00133	0.00943	CbGpPWpGaD
Fluphenazine—Vision blurred—Prednisolone—ankylosing spondylitis	0.0013	0.00445	CcSEcCtD
Fluphenazine—Erythema—Triamcinolone—ankylosing spondylitis	0.00127	0.00434	CcSEcCtD
Fluphenazine—Erythema—Methylprednisolone—ankylosing spondylitis	0.00127	0.00433	CcSEcCtD
Fluphenazine—Angioedema—Prednisolone—ankylosing spondylitis	0.00126	0.00431	CcSEcCtD
Fluphenazine—HTR6—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.00121	0.00858	CbGpPWpGaD
Fluphenazine—Asthma—Methotrexate—ankylosing spondylitis	0.00121	0.00411	CcSEcCtD
Fluphenazine—Hypertension—Prednisolone—ankylosing spondylitis	0.00119	0.00407	CcSEcCtD
Fluphenazine—Eosinophilia—Methotrexate—ankylosing spondylitis	0.00119	0.00407	CcSEcCtD
Fluphenazine—Angioedema—Triamcinolone—ankylosing spondylitis	0.00116	0.00397	CcSEcCtD
Fluphenazine—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00116	0.00396	CcSEcCtD
Fluphenazine—Erythema—Dexamethasone—ankylosing spondylitis	0.00115	0.00394	CcSEcCtD
Fluphenazine—Erythema—Betamethasone—ankylosing spondylitis	0.00115	0.00394	CcSEcCtD
Fluphenazine—Pancytopenia—Methotrexate—ankylosing spondylitis	0.00114	0.00391	CcSEcCtD
Fluphenazine—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00113	0.00385	CcSEcCtD
Fluphenazine—Upper respiratory tract infection—Methotrexate—ankylosing spondylitis	0.00112	0.00382	CcSEcCtD
Fluphenazine—Tachycardia—Prednisolone—ankylosing spondylitis	0.0011	0.00376	CcSEcCtD
Fluphenazine—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.0011	0.00375	CcSEcCtD
Fluphenazine—Hypertension—Triamcinolone—ankylosing spondylitis	0.0011	0.00375	CcSEcCtD
Fluphenazine—Hypertension—Methylprednisolone—ankylosing spondylitis	0.0011	0.00374	CcSEcCtD
Fluphenazine—Pneumonia—Methotrexate—ankylosing spondylitis	0.00108	0.00369	CcSEcCtD
Fluphenazine—Drowsiness—Methotrexate—ankylosing spondylitis	0.00107	0.00367	CcSEcCtD
Fluphenazine—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00106	0.00361	CcSEcCtD
Fluphenazine—Angioedema—Dexamethasone—ankylosing spondylitis	0.00105	0.0036	CcSEcCtD
Fluphenazine—Angioedema—Betamethasone—ankylosing spondylitis	0.00105	0.0036	CcSEcCtD
Fluphenazine—DRD1—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.00104	0.00739	CbGpPWpGaD
Fluphenazine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00104	0.00354	CcSEcCtD
Fluphenazine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00104	0.00353	CcSEcCtD
Fluphenazine—Tachycardia—Triamcinolone—ankylosing spondylitis	0.00101	0.00346	CcSEcCtD
Fluphenazine—HTR1A—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.00101	0.00716	CbGpPWpGaD
Fluphenazine—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.00101	0.00345	CcSEcCtD
Fluphenazine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00101	0.00343	CcSEcCtD
Fluphenazine—Erythema—Prednisone—ankylosing spondylitis	0.00101	0.00343	CcSEcCtD
Fluphenazine—Agranulocytosis—Methotrexate—ankylosing spondylitis	0.001	0.00342	CcSEcCtD
Fluphenazine—Hypertension—Betamethasone—ankylosing spondylitis	0.000996	0.0034	CcSEcCtD
Fluphenazine—Hypertension—Dexamethasone—ankylosing spondylitis	0.000996	0.0034	CcSEcCtD
Fluphenazine—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000968	0.0033	CcSEcCtD
Fluphenazine—Vision blurred—Prednisone—ankylosing spondylitis	0.000947	0.00323	CcSEcCtD
Fluphenazine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000942	0.00321	CcSEcCtD
Fluphenazine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000942	0.00321	CcSEcCtD
Fluphenazine—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000926	0.00316	CcSEcCtD
Fluphenazine—Agitation—Prednisone—ankylosing spondylitis	0.000924	0.00315	CcSEcCtD
Fluphenazine—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000919	0.00314	CcSEcCtD
Fluphenazine—Tachycardia—Betamethasone—ankylosing spondylitis	0.000919	0.00314	CcSEcCtD
Fluphenazine—Angioedema—Prednisone—ankylosing spondylitis	0.000918	0.00313	CcSEcCtD
Fluphenazine—Urticaria—Prednisolone—ankylosing spondylitis	0.000897	0.00306	CcSEcCtD
Fluphenazine—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.00089	0.00631	CbGpPWpGaD
Fluphenazine—Hypotension—Betamethasone—ankylosing spondylitis	0.00088	0.003	CcSEcCtD
Fluphenazine—Hypotension—Dexamethasone—ankylosing spondylitis	0.00088	0.003	CcSEcCtD
Fluphenazine—HTR2A—SIDS Susceptibility Pathways—RUNX3—ankylosing spondylitis	0.000874	0.00619	CbGpPWpGaD
Fluphenazine—Hypertension—Prednisone—ankylosing spondylitis	0.000868	0.00296	CcSEcCtD
Fluphenazine—CALM3—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000864	0.00612	CbGpPWpGaD
Fluphenazine—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000861	0.0061	CbGpPWpGaD
Fluphenazine—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—ankylosing spondylitis	0.000861	0.0061	CbGpPWpGaD
Fluphenazine—Erythema—Methotrexate—ankylosing spondylitis	0.00084	0.00287	CcSEcCtD
Fluphenazine—CALM1—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000836	0.00592	CbGpPWpGaD
Fluphenazine—CALM2—BCR signaling pathway—CD79A—ankylosing spondylitis	0.000836	0.00592	CbGpPWpGaD
Fluphenazine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000832	0.00284	CcSEcCtD
Fluphenazine—Urticaria—Triamcinolone—ankylosing spondylitis	0.000825	0.00281	CcSEcCtD
Fluphenazine—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000823	0.00281	CcSEcCtD
Fluphenazine—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000821	0.0028	CcSEcCtD
Fluphenazine—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.00082	0.0028	CcSEcCtD
Fluphenazine—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000819	0.00279	CcSEcCtD
Fluphenazine—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000819	0.00279	CcSEcCtD
Fluphenazine—Tachycardia—Prednisone—ankylosing spondylitis	0.000801	0.00273	CcSEcCtD
Fluphenazine—Skin disorder—Prednisone—ankylosing spondylitis	0.000797	0.00272	CcSEcCtD
Fluphenazine—Vision blurred—Methotrexate—ankylosing spondylitis	0.000792	0.0027	CcSEcCtD
Fluphenazine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000788	0.00558	CbGpPWpGaD
Fluphenazine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000765	0.00261	CcSEcCtD
Fluphenazine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000763	0.0026	CcSEcCtD
Fluphenazine—ABCB1—Allograft Rejection—HLA-C—ankylosing spondylitis	0.000753	0.00533	CbGpPWpGaD
Fluphenazine—Leukopenia—Methotrexate—ankylosing spondylitis	0.000752	0.00257	CcSEcCtD
Fluphenazine—Urticaria—Betamethasone—ankylosing spondylitis	0.000748	0.00255	CcSEcCtD
Fluphenazine—Urticaria—Dexamethasone—ankylosing spondylitis	0.000748	0.00255	CcSEcCtD
Fluphenazine—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000745	0.00254	CcSEcCtD
Fluphenazine—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000745	0.00254	CcSEcCtD
Fluphenazine—Pruritus—Triamcinolone—ankylosing spondylitis	0.000734	0.00251	CcSEcCtD
Fluphenazine—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000733	0.0025	CcSEcCtD
Fluphenazine—Decreased appetite—Prednisone—ankylosing spondylitis	0.000713	0.00243	CcSEcCtD
Fluphenazine—Headache—Prednisolone—ankylosing spondylitis	0.000707	0.00241	CcSEcCtD
Fluphenazine—Constipation—Prednisone—ankylosing spondylitis	0.000701	0.00239	CcSEcCtD
Fluphenazine—HTR1A—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000698	0.00494	CbGpPWpGaD
Fluphenazine—ABCB1—Allograft Rejection—IL17A—ankylosing spondylitis	0.000688	0.00488	CbGpPWpGaD
Fluphenazine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000686	0.00234	CcSEcCtD
Fluphenazine—HTR6—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000674	0.00477	CbGpPWpGaD
Fluphenazine—Nausea—Prednisolone—ankylosing spondylitis	0.000671	0.00229	CcSEcCtD
Fluphenazine—Pruritus—Dexamethasone—ankylosing spondylitis	0.000666	0.00227	CcSEcCtD
Fluphenazine—Pruritus—Betamethasone—ankylosing spondylitis	0.000666	0.00227	CcSEcCtD
Fluphenazine—Skin disorder—Methotrexate—ankylosing spondylitis	0.000666	0.00227	CcSEcCtD
Fluphenazine—CALM3—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000654	0.00463	CbGpPWpGaD
Fluphenazine—Urticaria—Prednisone—ankylosing spondylitis	0.000652	0.00222	CcSEcCtD
Fluphenazine—Headache—Triamcinolone—ankylosing spondylitis	0.00065	0.00222	CcSEcCtD
Fluphenazine—Headache—Methylprednisolone—ankylosing spondylitis	0.000649	0.00221	CcSEcCtD
Fluphenazine—Body temperature increased—Prednisone—ankylosing spondylitis	0.000648	0.00221	CcSEcCtD
Fluphenazine—Hypotension—Methotrexate—ankylosing spondylitis	0.000641	0.00219	CcSEcCtD
Fluphenazine—ABCB1—Allograft Rejection—IL12B—ankylosing spondylitis	0.00064	0.00453	CbGpPWpGaD
Fluphenazine—CALM1—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000632	0.00448	CbGpPWpGaD
Fluphenazine—CALM2—Cellular roles of Anthrax toxin—TNF—ankylosing spondylitis	0.000632	0.00448	CbGpPWpGaD
Fluphenazine—CALM3—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000628	0.00445	CbGpPWpGaD
Fluphenazine—Nausea—Triamcinolone—ankylosing spondylitis	0.000617	0.0021	CcSEcCtD
Fluphenazine—Nausea—Methylprednisolone—ankylosing spondylitis	0.000615	0.0021	CcSEcCtD
Fluphenazine—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000611	0.00209	CcSEcCtD
Fluphenazine—Somnolence—Methotrexate—ankylosing spondylitis	0.000609	0.00208	CcSEcCtD
Fluphenazine—CALM1—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000608	0.00431	CbGpPWpGaD
Fluphenazine—CALM2—Downstream signaling in naïve CD8+ T cells—HLA-A—ankylosing spondylitis	0.000608	0.00431	CbGpPWpGaD
Fluphenazine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000604	0.00206	CcSEcCtD
Fluphenazine—HTR2A—SIDS Susceptibility Pathways—IL1RN—ankylosing spondylitis	0.000603	0.00427	CbGpPWpGaD
Fluphenazine—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000596	0.00203	CcSEcCtD
Fluphenazine—Headache—Betamethasone—ankylosing spondylitis	0.00059	0.00201	CcSEcCtD
Fluphenazine—Headache—Dexamethasone—ankylosing spondylitis	0.00059	0.00201	CcSEcCtD
Fluphenazine—CALM3—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.000589	0.00417	CbGpPWpGaD
Fluphenazine—DRD1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00058	0.00411	CbGpPWpGaD
Fluphenazine—Pruritus—Prednisone—ankylosing spondylitis	0.00058	0.00198	CcSEcCtD
Fluphenazine—HTR6—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000578	0.00409	CbGpPWpGaD
Fluphenazine—DRD3—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000573	0.00406	CbGpPWpGaD
Fluphenazine—CALM2—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00057	0.00404	CbGpPWpGaD
Fluphenazine—CALM1—Adaptive Immune System—KIR3DL1—ankylosing spondylitis	0.00057	0.00404	CbGpPWpGaD
Fluphenazine—Nausea—Dexamethasone—ankylosing spondylitis	0.000559	0.00191	CcSEcCtD
Fluphenazine—Nausea—Betamethasone—ankylosing spondylitis	0.000559	0.00191	CcSEcCtD
Fluphenazine—Urticaria—Methotrexate—ankylosing spondylitis	0.000545	0.00186	CcSEcCtD
Fluphenazine—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000542	0.00185	CcSEcCtD
Fluphenazine—CALM3—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000521	0.00369	CbGpPWpGaD
Fluphenazine—CALM3—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.00052	0.00368	CbGpPWpGaD
Fluphenazine—Headache—Prednisone—ankylosing spondylitis	0.000514	0.00175	CcSEcCtD
Fluphenazine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000505	0.00172	CcSEcCtD
Fluphenazine—CALM2—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000504	0.00357	CbGpPWpGaD
Fluphenazine—CALM1—DAP12 interactions—HLA-C—ankylosing spondylitis	0.000504	0.00357	CbGpPWpGaD
Fluphenazine—CALM1—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000503	0.00356	CbGpPWpGaD
Fluphenazine—CALM2—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000503	0.00356	CbGpPWpGaD
Fluphenazine—HTR1A—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000503	0.00356	CbGpPWpGaD
Fluphenazine—HTR1A—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.0005	0.00354	CbGpPWpGaD
Fluphenazine—HTR1A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000499	0.00353	CbGpPWpGaD
Fluphenazine—DRD1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000497	0.00352	CbGpPWpGaD
Fluphenazine—HTR2C—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000496	0.00352	CbGpPWpGaD
Fluphenazine—DRD3—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000491	0.00347	CbGpPWpGaD
Fluphenazine—Nausea—Prednisone—ankylosing spondylitis	0.000487	0.00166	CcSEcCtD
Fluphenazine—Pruritus—Methotrexate—ankylosing spondylitis	0.000485	0.00165	CcSEcCtD
Fluphenazine—ABCB1—Allograft Rejection—IL1A—ankylosing spondylitis	0.000471	0.00333	CbGpPWpGaD
Fluphenazine—ABCB1—Allograft Rejection—CD40LG—ankylosing spondylitis	0.000468	0.00331	CbGpPWpGaD
Fluphenazine—ABCB1—Allograft Rejection—IL10—ankylosing spondylitis	0.000468	0.00331	CbGpPWpGaD
Fluphenazine—ABCB1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000447	0.00317	CbGpPWpGaD
Fluphenazine—ABCB1—Allograft Rejection—HLA-B—ankylosing spondylitis	0.000445	0.00315	CbGpPWpGaD
Fluphenazine—HTR6—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.00044	0.00312	CbGpPWpGaD
Fluphenazine—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000438	0.0031	CbGpPWpGaD
Fluphenazine—HTR2A—SIDS Susceptibility Pathways—IL1A—ankylosing spondylitis	0.000434	0.00307	CbGpPWpGaD
Fluphenazine—HTR2A—SIDS Susceptibility Pathways—IL10—ankylosing spondylitis	0.000432	0.00306	CbGpPWpGaD
Fluphenazine—HTR2A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000431	0.00305	CbGpPWpGaD
Fluphenazine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00043	0.00305	CbGpPWpGaD
Fluphenazine—Headache—Methotrexate—ankylosing spondylitis	0.000429	0.00147	CcSEcCtD
Fluphenazine—HTR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000428	0.00303	CbGpPWpGaD
Fluphenazine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000425	0.00301	CbGpPWpGaD
Fluphenazine—ABCB1—Allograft Rejection—HLA-A—ankylosing spondylitis	0.000412	0.00292	CbGpPWpGaD
Fluphenazine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000409	0.0029	CbGpPWpGaD
Fluphenazine—Nausea—Methotrexate—ankylosing spondylitis	0.000407	0.00139	CcSEcCtD
Fluphenazine—ADRA2A—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000392	0.00278	CbGpPWpGaD
Fluphenazine—DRD1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000379	0.00268	CbGpPWpGaD
Fluphenazine—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000375	0.00266	CbGpPWpGaD
Fluphenazine—DRD3—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000374	0.00265	CbGpPWpGaD
Fluphenazine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000369	0.00262	CbGpPWpGaD
Fluphenazine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000369	0.00261	CbGpPWpGaD
Fluphenazine—CALM3—B Cell Activation—CD79A—ankylosing spondylitis	0.000368	0.0026	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—KIR3DL1—ankylosing spondylitis	0.000357	0.00253	CbGpPWpGaD
Fluphenazine—CALM1—B Cell Activation—CD79A—ankylosing spondylitis	0.000356	0.00252	CbGpPWpGaD
Fluphenazine—CALM2—B Cell Activation—CD79A—ankylosing spondylitis	0.000356	0.00252	CbGpPWpGaD
Fluphenazine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000355	0.00252	CbGpPWpGaD
Fluphenazine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000354	0.00251	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—KIR3DL1—ankylosing spondylitis	0.000346	0.00245	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—KIR3DL1—ankylosing spondylitis	0.000346	0.00245	CbGpPWpGaD
Fluphenazine—CALM3—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000339	0.0024	CbGpPWpGaD
Fluphenazine—CALM3—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000338	0.0024	CbGpPWpGaD
Fluphenazine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000336	0.00238	CbGpPWpGaD
Fluphenazine—CALM1—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000328	0.00232	CbGpPWpGaD
Fluphenazine—CALM2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—ankylosing spondylitis	0.000328	0.00232	CbGpPWpGaD
Fluphenazine—CALM2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000327	0.00232	CbGpPWpGaD
Fluphenazine—CALM1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000327	0.00232	CbGpPWpGaD
Fluphenazine—HTR1A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000326	0.00231	CbGpPWpGaD
Fluphenazine—HTR2C—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000324	0.00229	CbGpPWpGaD
Fluphenazine—CALM3—Innate Immune System—CARD9—ankylosing spondylitis	0.000322	0.00228	CbGpPWpGaD
Fluphenazine—CALM1—Innate Immune System—CARD9—ankylosing spondylitis	0.000312	0.00221	CbGpPWpGaD
Fluphenazine—CALM2—Innate Immune System—CARD9—ankylosing spondylitis	0.000312	0.00221	CbGpPWpGaD
Fluphenazine—CALM3—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000308	0.00218	CbGpPWpGaD
Fluphenazine—CALM2—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000304	0.00215	CbGpPWpGaD
Fluphenazine—CALM1—Cardiac Hypertrophic Response—TNF—ankylosing spondylitis	0.000304	0.00215	CbGpPWpGaD
Fluphenazine—CALM2—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000298	0.00211	CbGpPWpGaD
Fluphenazine—CALM1—DAP12 interactions—HLA-B—ankylosing spondylitis	0.000298	0.00211	CbGpPWpGaD
Fluphenazine—DRD2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000286	0.00202	CbGpPWpGaD
Fluphenazine—HTR2A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000281	0.00199	CbGpPWpGaD
Fluphenazine—HRH1—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000281	0.00199	CbGpPWpGaD
Fluphenazine—CALM3—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000271	0.00192	CbGpPWpGaD
Fluphenazine—CALM1—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000263	0.00186	CbGpPWpGaD
Fluphenazine—CALM2—Downstream signaling in naïve CD8+ T cells—TNF—ankylosing spondylitis	0.000263	0.00186	CbGpPWpGaD
Fluphenazine—ADRA2A—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000256	0.00181	CbGpPWpGaD
Fluphenazine—CALM3—Disease—ANTXR2—ankylosing spondylitis	0.00025	0.00177	CbGpPWpGaD
Fluphenazine—HTR6—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000249	0.00176	CbGpPWpGaD
Fluphenazine—CALM2—Disease—ANTXR2—ankylosing spondylitis	0.000242	0.00171	CbGpPWpGaD
Fluphenazine—CALM1—Disease—ANTXR2—ankylosing spondylitis	0.000242	0.00171	CbGpPWpGaD
Fluphenazine—CALM3—Alzheimers Disease—TNF—ankylosing spondylitis	0.000235	0.00166	CbGpPWpGaD
Fluphenazine—CALM2—Alzheimers Disease—TNF—ankylosing spondylitis	0.000227	0.00161	CbGpPWpGaD
Fluphenazine—CALM1—Alzheimers Disease—TNF—ankylosing spondylitis	0.000227	0.00161	CbGpPWpGaD
Fluphenazine—HTR6—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000226	0.0016	CbGpPWpGaD
Fluphenazine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000219	0.00155	CbGpPWpGaD
Fluphenazine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000219	0.00155	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—IL1R2—ankylosing spondylitis	0.000217	0.00153	CbGpPWpGaD
Fluphenazine—CALM1—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000216	0.00153	CbGpPWpGaD
Fluphenazine—CALM2—MicroRNAs in cardiomyocyte hypertrophy—TNF—ankylosing spondylitis	0.000216	0.00153	CbGpPWpGaD
Fluphenazine—DRD1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000214	0.00152	CbGpPWpGaD
Fluphenazine—DRD3—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000211	0.0015	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—IL1R2—ankylosing spondylitis	0.000209	0.00148	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—IL1R2—ankylosing spondylitis	0.000209	0.00148	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—ERAP1—ankylosing spondylitis	0.000205	0.00145	CbGpPWpGaD
Fluphenazine—CALM3—Innate Immune System—HLA-C—ankylosing spondylitis	0.000202	0.00143	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—ERAP1—ankylosing spondylitis	0.000199	0.00141	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—ERAP1—ankylosing spondylitis	0.000199	0.00141	CbGpPWpGaD
Fluphenazine—CALM1—Innate Immune System—HLA-C—ankylosing spondylitis	0.000196	0.00139	CbGpPWpGaD
Fluphenazine—CALM2—Innate Immune System—HLA-C—ankylosing spondylitis	0.000196	0.00139	CbGpPWpGaD
Fluphenazine—CALM3—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000194	0.00138	CbGpPWpGaD
Fluphenazine—DRD1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000194	0.00138	CbGpPWpGaD
Fluphenazine—DRD3—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000192	0.00136	CbGpPWpGaD
Fluphenazine—HTR1A—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.00019	0.00135	CbGpPWpGaD
Fluphenazine—CALM2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000188	0.00133	CbGpPWpGaD
Fluphenazine—CALM1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000188	0.00133	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—CARD9—ankylosing spondylitis	0.000188	0.00133	CbGpPWpGaD
Fluphenazine—HTR1A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000184	0.0013	CbGpPWpGaD
Fluphenazine—HTR2C—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000183	0.0013	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—CARD9—ankylosing spondylitis	0.000182	0.00129	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—CARD9—ankylosing spondylitis	0.000182	0.00129	CbGpPWpGaD
Fluphenazine—ABCB1—Allograft Rejection—TNF—ankylosing spondylitis	0.000178	0.00126	CbGpPWpGaD
Fluphenazine—HTR1A—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000167	0.00118	CbGpPWpGaD
Fluphenazine—HTR2C—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000166	0.00118	CbGpPWpGaD
Fluphenazine—HTR2A—SIDS Susceptibility Pathways—TNF—ankylosing spondylitis	0.000164	0.00116	CbGpPWpGaD
Fluphenazine—DRD2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000162	0.00114	CbGpPWpGaD
Fluphenazine—HTR6—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000161	0.00114	CbGpPWpGaD
Fluphenazine—HTR2A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000159	0.00113	CbGpPWpGaD
Fluphenazine—HRH1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000159	0.00112	CbGpPWpGaD
Fluphenazine—CALM3—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000148	0.00105	CbGpPWpGaD
Fluphenazine—CALM3—Disease—B3GNT2—ankylosing spondylitis	0.000147	0.00104	CbGpPWpGaD
Fluphenazine—DRD2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000147	0.00104	CbGpPWpGaD
Fluphenazine—ADRA2A—GPCR downstream signaling—PTGER4—ankylosing spondylitis	0.000145	0.00102	CbGpPWpGaD
Fluphenazine—HTR2A—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000144	0.00102	CbGpPWpGaD
Fluphenazine—HRH1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000144	0.00102	CbGpPWpGaD
Fluphenazine—CALM1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000143	0.00102	CbGpPWpGaD
Fluphenazine—CALM2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000143	0.00102	CbGpPWpGaD
Fluphenazine—CALM2—Disease—B3GNT2—ankylosing spondylitis	0.000143	0.00101	CbGpPWpGaD
Fluphenazine—CALM1—Disease—B3GNT2—ankylosing spondylitis	0.000143	0.00101	CbGpPWpGaD
Fluphenazine—DRD1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000138	0.00098	CbGpPWpGaD
Fluphenazine—DRD3—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000137	0.000967	CbGpPWpGaD
Fluphenazine—ADRA2A—Metabolism—B3GNT2—ankylosing spondylitis	0.000135	0.000958	CbGpPWpGaD
Fluphenazine—HTR6—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000133	0.000944	CbGpPWpGaD
Fluphenazine—ADRA2A—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000131	0.00093	CbGpPWpGaD
Fluphenazine—CYP2E1—Metabolism—B3GNT2—ankylosing spondylitis	0.000124	0.00088	CbGpPWpGaD
Fluphenazine—CALM3—Metabolism—B3GNT2—ankylosing spondylitis	0.000123	0.000874	CbGpPWpGaD
Fluphenazine—CALM3—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000121	0.000856	CbGpPWpGaD
Fluphenazine—CALM3—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.00012	0.000849	CbGpPWpGaD
Fluphenazine—CALM3—Innate Immune System—HLA-B—ankylosing spondylitis	0.00012	0.000848	CbGpPWpGaD
Fluphenazine—CALM1—Metabolism—B3GNT2—ankylosing spondylitis	0.000119	0.000846	CbGpPWpGaD
Fluphenazine—CALM2—Metabolism—B3GNT2—ankylosing spondylitis	0.000119	0.000846	CbGpPWpGaD
Fluphenazine—HTR1A—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000119	0.000843	CbGpPWpGaD
Fluphenazine—HTR2C—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000118	0.000838	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—HLA-C—ankylosing spondylitis	0.000118	0.000835	CbGpPWpGaD
Fluphenazine—CALM2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000117	0.000828	CbGpPWpGaD
Fluphenazine—CALM1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000117	0.000828	CbGpPWpGaD
Fluphenazine—CALM1—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000116	0.000821	CbGpPWpGaD
Fluphenazine—CALM2—Signaling by GPCR—PTGER4—ankylosing spondylitis	0.000116	0.000821	CbGpPWpGaD
Fluphenazine—CALM1—Innate Immune System—HLA-B—ankylosing spondylitis	0.000116	0.00082	CbGpPWpGaD
Fluphenazine—CALM2—Innate Immune System—HLA-B—ankylosing spondylitis	0.000116	0.00082	CbGpPWpGaD
Fluphenazine—CALM3—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000115	0.000814	CbGpPWpGaD
Fluphenazine—DRD1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000115	0.000813	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—HLA-C—ankylosing spondylitis	0.000114	0.000808	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—HLA-C—ankylosing spondylitis	0.000114	0.000808	CbGpPWpGaD
Fluphenazine—DRD3—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000113	0.000802	CbGpPWpGaD
Fluphenazine—CALM1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000111	0.000787	CbGpPWpGaD
Fluphenazine—CALM2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000111	0.000787	CbGpPWpGaD
Fluphenazine—CALM3—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000106	0.000754	CbGpPWpGaD
Fluphenazine—CALM3—Innate Immune System—CRP—ankylosing spondylitis	0.000106	0.000749	CbGpPWpGaD
Fluphenazine—DRD2—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000104	0.00074	CbGpPWpGaD
Fluphenazine—CALM2—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000103	0.00073	CbGpPWpGaD
Fluphenazine—CALM1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000103	0.00073	CbGpPWpGaD
Fluphenazine—HTR2A—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000103	0.000728	CbGpPWpGaD
Fluphenazine—HRH1—Signaling by GPCR—MMP3—ankylosing spondylitis	0.000103	0.000726	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—IL1RN—ankylosing spondylitis	0.000102	0.000725	CbGpPWpGaD
Fluphenazine—CALM2—Innate Immune System—CRP—ankylosing spondylitis	0.000102	0.000725	CbGpPWpGaD
Fluphenazine—CALM1—Innate Immune System—CRP—ankylosing spondylitis	0.000102	0.000725	CbGpPWpGaD
Fluphenazine—CALM3—Innate Immune System—TLR4—ankylosing spondylitis	0.000101	0.000718	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—IL1RN—ankylosing spondylitis	9.91e-05	0.000702	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—IL1RN—ankylosing spondylitis	9.91e-05	0.000702	CbGpPWpGaD
Fluphenazine—HTR1A—Signaling Pathways—PTGER4—ankylosing spondylitis	9.87e-05	0.000699	CbGpPWpGaD
Fluphenazine—HTR2C—Signaling Pathways—PTGER4—ankylosing spondylitis	9.82e-05	0.000695	CbGpPWpGaD
Fluphenazine—CALM1—Innate Immune System—TLR4—ankylosing spondylitis	9.81e-05	0.000695	CbGpPWpGaD
Fluphenazine—CALM2—Innate Immune System—TLR4—ankylosing spondylitis	9.81e-05	0.000695	CbGpPWpGaD
Fluphenazine—HTR6—Signaling Pathways—MMP3—ankylosing spondylitis	9.49e-05	0.000672	CbGpPWpGaD
Fluphenazine—ABCB1—Metabolism—B3GNT2—ankylosing spondylitis	9.35e-05	0.000662	CbGpPWpGaD
Fluphenazine—ADRA2A—Signaling by GPCR—MMP3—ankylosing spondylitis	9.35e-05	0.000662	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—CD79A—ankylosing spondylitis	8.99e-05	0.000637	CbGpPWpGaD
Fluphenazine—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	8.81e-05	0.000624	CbGpPWpGaD
Fluphenazine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.79e-05	0.000623	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—CD79A—ankylosing spondylitis	8.7e-05	0.000616	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—CD79A—ankylosing spondylitis	8.7e-05	0.000616	CbGpPWpGaD
Fluphenazine—DRD2—Signaling Pathways—PTGER4—ankylosing spondylitis	8.67e-05	0.000614	CbGpPWpGaD
Fluphenazine—CALM3—Signaling by GPCR—MMP3—ankylosing spondylitis	8.53e-05	0.000604	CbGpPWpGaD
Fluphenazine—HTR2A—Signaling Pathways—PTGER4—ankylosing spondylitis	8.53e-05	0.000604	CbGpPWpGaD
Fluphenazine—HRH1—Signaling Pathways—PTGER4—ankylosing spondylitis	8.51e-05	0.000603	CbGpPWpGaD
Fluphenazine—CALM2—Signaling by GPCR—MMP3—ankylosing spondylitis	8.25e-05	0.000585	CbGpPWpGaD
Fluphenazine—CALM1—Signaling by GPCR—MMP3—ankylosing spondylitis	8.25e-05	0.000585	CbGpPWpGaD
Fluphenazine—DRD1—Signaling Pathways—MMP3—ankylosing spondylitis	8.17e-05	0.000579	CbGpPWpGaD
Fluphenazine—DRD3—Signaling Pathways—MMP3—ankylosing spondylitis	8.06e-05	0.000571	CbGpPWpGaD
Fluphenazine—ADRA2A—Signaling Pathways—PTGER4—ankylosing spondylitis	7.76e-05	0.000549	CbGpPWpGaD
Fluphenazine—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	7.47e-05	0.000529	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—IL1A—ankylosing spondylitis	7.37e-05	0.000522	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—CD40LG—ankylosing spondylitis	7.33e-05	0.000519	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—IL1A—ankylosing spondylitis	7.13e-05	0.000505	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—IL1A—ankylosing spondylitis	7.13e-05	0.000505	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—CD40LG—ankylosing spondylitis	7.09e-05	0.000502	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—CD40LG—ankylosing spondylitis	7.09e-05	0.000502	CbGpPWpGaD
Fluphenazine—CALM3—Signaling Pathways—PTGER4—ankylosing spondylitis	7.08e-05	0.000501	CbGpPWpGaD
Fluphenazine—HTR1A—Signaling Pathways—MMP3—ankylosing spondylitis	7.03e-05	0.000498	CbGpPWpGaD
Fluphenazine—HTR2C—Signaling Pathways—MMP3—ankylosing spondylitis	6.99e-05	0.000495	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—HLA-B—ankylosing spondylitis	6.97e-05	0.000494	CbGpPWpGaD
Fluphenazine—CALM2—Signaling Pathways—PTGER4—ankylosing spondylitis	6.85e-05	0.000485	CbGpPWpGaD
Fluphenazine—CALM1—Signaling Pathways—PTGER4—ankylosing spondylitis	6.85e-05	0.000485	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—HLA-B—ankylosing spondylitis	6.74e-05	0.000478	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—HLA-B—ankylosing spondylitis	6.74e-05	0.000478	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—HLA-A—ankylosing spondylitis	6.46e-05	0.000457	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—HLA-A—ankylosing spondylitis	6.25e-05	0.000443	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—HLA-A—ankylosing spondylitis	6.25e-05	0.000443	CbGpPWpGaD
Fluphenazine—DRD2—Signaling Pathways—MMP3—ankylosing spondylitis	6.17e-05	0.000437	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—CRP—ankylosing spondylitis	6.16e-05	0.000436	CbGpPWpGaD
Fluphenazine—HTR2A—Signaling Pathways—MMP3—ankylosing spondylitis	6.07e-05	0.00043	CbGpPWpGaD
Fluphenazine—HRH1—Signaling Pathways—MMP3—ankylosing spondylitis	6.06e-05	0.000429	CbGpPWpGaD
Fluphenazine—CALM3—Disease—HLA-A—ankylosing spondylitis	5.96e-05	0.000422	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—CRP—ankylosing spondylitis	5.96e-05	0.000422	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—CRP—ankylosing spondylitis	5.96e-05	0.000422	CbGpPWpGaD
Fluphenazine—CALM3—Immune System—TLR4—ankylosing spondylitis	5.91e-05	0.000418	CbGpPWpGaD
Fluphenazine—CALM1—Disease—HLA-A—ankylosing spondylitis	5.77e-05	0.000409	CbGpPWpGaD
Fluphenazine—CALM2—Disease—HLA-A—ankylosing spondylitis	5.77e-05	0.000409	CbGpPWpGaD
Fluphenazine—CALM1—Immune System—TLR4—ankylosing spondylitis	5.72e-05	0.000405	CbGpPWpGaD
Fluphenazine—CALM2—Immune System—TLR4—ankylosing spondylitis	5.72e-05	0.000405	CbGpPWpGaD
Fluphenazine—ADRA2A—Signaling Pathways—MMP3—ankylosing spondylitis	5.52e-05	0.000391	CbGpPWpGaD
Fluphenazine—CALM3—Signaling Pathways—MMP3—ankylosing spondylitis	5.04e-05	0.000357	CbGpPWpGaD
Fluphenazine—CALM2—Signaling Pathways—MMP3—ankylosing spondylitis	4.88e-05	0.000345	CbGpPWpGaD
Fluphenazine—CALM1—Signaling Pathways—MMP3—ankylosing spondylitis	4.88e-05	0.000345	CbGpPWpGaD
